Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Richard Greil, Oleh Zagrijtschuk et al.|Blood|2015Cited by 186
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2bNicole C.C. Them, Róbert Královics, Klaudia Bagienski et al.|American Journal of Hematology|2014Cited by 54
Influence of platelet and white blood cell counts on major thrombosis – analysis from a patient registry in essential thrombocythemiaVeronika Buxhofer‐Ausch, Heinz Gisslinger, Michael Steurer et al.|European Journal Of Haematology|2016Cited by 42
Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemiaVeronika Buxhofer‐Ausch, Heinz Gisslinger, Michael Steurer et al.|European Journal Of Haematology|2018Cited by 18
Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera StudyHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2013Cited by 9